<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-specific immunity of insulin-like growth factor-binding protein-2 (IGFBP-2) has been reported in several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to assess the role of serum IGFBP-2 antibodies (IGFBP-2 Abs) in early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detection </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: <z:hpo ids='HP_0009733'>Glioma</z:hpo> and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) were used as models </plain></SENT>
<SENT sid="3" pm="."><plain>Serum IGFBP-2 and IGFBP-2 Abs were measured in 260 tumor patients (145 <z:hpo ids='HP_0009733'>gliomas</z:hpo>, 45 colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath>, and 70 CRCs) and 141 controls </plain></SENT>
<SENT sid="4" pm="."><plain>Receiver operating characteristic curves were applied </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Serum IGFBP-2 Ab levels were significantly elevated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (mean: 82 ng/ml, median: 17 ng/ml, range: 0-1387 ng/ml) compared with controls (11, 0, 0-212 ng/ml) (P &lt; 0.0001) and higher in early than <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancers</z:e> opposite of serum IGFBP-2 levels </plain></SENT>
<SENT sid="6" pm="."><plain>IGFBP-2 Abs effectively discriminated between controls and grade II and III <z:hpo ids='HP_0009733'>gliomas</z:hpo> [area under the curve (AUC): 0.821-0.864; 95% confidence interval (CI) = 0.762-0.936; P &lt; 0.0001], and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> I-II (AUC: 0.668; 95% CI = 0.566-0.770; P = 0.002) as well as indicative of advanced <z:mpath ids='MPATH_491'>polyps</z:mpath> at high risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (AUC: 0.72; 95% CI = 0.630-0.811; P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>The sensitivity and specificity for diagnosing grade II-III <z:hpo ids='HP_0009733'>gliomas</z:hpo> reached 66%-84% and 81% </plain></SENT>
<SENT sid="8" pm="."><plain>Combined serum IGFBP-2 and IGFBP-2 Abs augmented the discriminative power of <z:hpo ids='HP_0000001'>all</z:hpo> stage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (AUC: 0.823), <z:hpo ids='HP_0009733'>gliomas</z:hpo> (AUC: 0.800), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (AUC = 0.917) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Our results first demonstrate IGFBP-2 Abs for early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detection and in combination of serum IGFBP-2 for improved <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
</text></document>